<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205750</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0132</org_study_id>
    <nct_id>NCT01205750</nct_id>
  </id_info>
  <brief_title>Hepatic Insulin Sensitivity and Very Low Density Lipoprotein Triglyceride (VLDL-TG) Kinetics</brief_title>
  <official_title>Basal and Insulin Mediated VLDL-triglyceride Kinetics in Obesity; Relationship With Hepatic Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is associated with dyslipidemia, which is a major risk factor for coronary heart
      disease. Triglycerides (TG) and cholesterol are transported in the system of lipoproteins,
      and the metabolism of these lipids in plasma is closely interrelated. Evidence suggests that
      increased concentration of very low-density lipoprotein triglyceride (VLDL-TG) is a central
      pathophysiological feature of the lipid and lipoprotein abnormalities in dyslipidemia.

      The primary objective of this study is to investigate VLDL-TG kinetics and hepatic insulin
      sensitivity in age-matched obese and lean, healthy men in the postabsorptive state and during
      acute hyperinsulinemia using VLDL-TG and glucose tracers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extensive description not included.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL-TG kinetics</measure>
    <time_frame>VLDL-TG kinetics are determined postabsorptively (250 minues) and during acute hyperinsulinemia (450 minutes)</time_frame>
    <description>VLDL-TG secretion rates(umol/min) and clearance rates (ml/min)are determined during 30 min steady state periods postabsorptively and using acute hyperinsulinemia using primed-constant infusion of ex vivo-labelled 14C-VLDL-TG tracer and traditional tracer dilution technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic insulin sensitivity</measure>
    <time_frame>Glucose kinetics are determined postabsorptively (250 minues) and during acute hyperinsulinemia (450 minutes)</time_frame>
    <description>Hepatic glucose production (mg/min) is determined during 30 min steady state periods postabsorptively and during acute hyperinsulinemia using primed constant infusion og 3H-glucose tracer and traditional tracer dilution technique.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Glucose clamp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose clamp</intervention_name>
    <description>450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min</description>
    <arm_group_label>Glucose clamp</arm_group_label>
    <other_name>Human insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  BMI &lt; 25 kg/m2 or &gt; 30 kg/m2

          -  Informed consent

        Exclusion Criteria:

          -  Alcohol misuse

          -  Smoking

          -  Use of prescription drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren Nielsen, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Søren Nielsen, DMSc</name_title>
    <organization>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Denmark</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

